Lifeward Ltd.

Lifeward Ltd. announced it will report its second quarter 2026 financial results on Friday, August 14, 2026. The company plans to issue a press release and file its quarterly report with the SEC before 9:30 a.m. ET on that day. Lifeward also stated that it will not be conducting a conference call in conjunction with the earnings release.

Lifeward Ltd. announced a pilot program with Ottobock Care, a leading orthotics and prosthetics patient care organization in the U.S. This six-month program is designed to expand patient access to Lifeward's ReWalk® 7 Personal Exoskeleton by leveraging Ottobock Care's extensive clinical expertise and patient care infrastructure. The initiative aims to increase awareness, develop regional expertise, and build local support for patient evaluation and training, with the goal of establishing a scalable model for national distribution.

Lifeward Ltd. entered into a securities purchase agreement on June 30, 2026, closing on July 6, 2026, to issue senior secured convertible notes and accompanying warrants to certain investors. The company initially issued $5,580,000.00 in notes and warrants, with the potential for a second tranche of $5,580,000.00 subject to specific conditions. The notes carry an 8.0% annual interest rate, convertible into ordinary shares at $5.40 per share, and mature in three years. Additionally, the company amended and restated previously issued notes and warrants to revise certain provisions.

Lifeward Ltd. announced it secured approximately $5.6 million in initial financing through a securities purchase agreement with institutional and accredited investors. This funding, consisting of senior secured convertible notes and warrants, is part of a strategic financing framework. Investors have committed an additional $5.6 million upon achieving specific commercial milestones, such as a 150% increase in ReWalk unit sales or the company's shares trading above $13.80 for ten consecutive days. This capital aims to accelerate the commercialization of its restorative healthcare platform and advance its product portfolio.

Lifeward Ltd. reported a net loss of $10.8 million for the first quarter of 2026, widening from a $4.8 million loss in the prior year. Revenues also declined to $3.9 million from $5.0 million. The company disclosed substantial doubt about its ability to continue as a going concern due to expected operating losses and negative cash flows, despite completing the acquisition of Oratech Pharmaceuticals Ltd. in March 2026 and securing additional financing.

Lifeward Ltd. announced the appointment of Keith D. Rose, M.D., as its new Chief Medical Officer. Dr. Rose, who previously served as Vice President, Medical Affairs and Medical Director, Neurosciences at Lifeward, will now lead the company's global medical strategy. This promotion reflects Lifeward’s continued investment in clinical innovation and evidence generation across its expanding med-tech rehabilitation and biomed technology portfolio, leveraging Dr. Rose's three decades of experience in rehabilitation medicine and neuroscience.

Lifeward Ltd. announced its financial results for the first quarter ended March 31, 2026, reporting a revenue of $3.9 million and a net loss of $10.8 million. The company successfully closed a strategic transaction with Oramed, receiving $10 million in financing, and acquired Oratech, which brings $6.5 million in cash and Protein Oral Delivery™ biomed technology. Lifeward also acquired upper body exoskeleton technology and reduced its quarterly operating cash burn by 33% year-over-year. The company will delay filing its Form 10-Q to finalize accounting for the strategic transaction.

Lifeward Ltd. announced it will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the release, President and CEO Mark Grant and CFO Almog Adar will host a conference call and live webcast at 8:30 a.m. EDT to discuss the results. Investors and analysts can access the call via provided phone numbers or a webcast link on the Company's website.

Lifeward Ltd. announced new clinical data on its ReWalk Personal Exoskeleton, presented at the ASIA 2026 Annual Scientific Meeting. The data, spanning over a decade, demonstrates a consistently favorable and improving safety profile, with a global lifetime fracture prevalence of just 3% since 2013, declining to 0.3% over the past six years. Notably, zero fractures were reported among 97 German users since 2018, reinforcing confidence in the device and supporting its expanded adoption for spinal cord injury mobility.

Lifeward Ltd. announced that Jeannine Lynch, Vice President of Strategy and Market Access, will depart from her position effective May 3, 2026. Her employment is being terminated without cause, and she will receive severance and other benefits in accordance with the terms of her Employment Agreement.